Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

Inclusion Criteria

• •Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the breast with marrow involvement.
• •Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29
• •Stable disease (defined as fluctuation of \<50U in CA15-3 or CA27-29 value) for at least 3 months while either on no breast-cancer therapy or while on current therapy (Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or trastuzumab chemotherapy is not allowed)
• •ability to understand the risks, benefits, and procedures and provide written informed consent.
• •less than 28 days prior to enrollment since last surgery and/or radiation therapy.
• •performance status \<=2 on the ECOG performance scale and life expectancy of greater than 12 months
• •NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is abnormal, patient must have an echocardiogram showing a left ventricular ejection fraction greater than the lower limits of normal.
• •Acceptable pulmonary function. if questionable, a pulmonary function test will be performed.
• •negative serology for hepatitis B, C and HIV.
• •red cell mean corpuscular volume \>- 80 cu. mm, hemoglobin \>- 8g/dl, platelet count \>- 100,000/dl: AST, ALT, LDH \<-2 times the Upper limit of normal
• •Serum creatinine \< 1.6 mg/dL
• •for women with child bearing potential, Negative urine pregnancy test within 7 days of registration and willingness to use an approved contraceptive method while participating in this trial.